A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
05 2019
Historique:
received: 01 08 2018
revised: 31 10 2018
accepted: 29 12 2018
pubmed: 28 4 2019
medline: 27 5 2020
entrez: 28 4 2019
Statut: ppublish

Résumé

Unlike for glucose, uptake of the brain's main alternative fuel, ketones, remains normal in mild cognitive impairment (MCI). Ketogenic medium chain triglycerides (kMCTs) could improve cognition in MCI by providing the brain with more fuel. Fifty-two subjects with MCI were blindly randomized to 30 g/day of kMCT or matching placebo. Brain ketone and glucose metabolism (quantified by positron emission tomography; primary outcome) and cognitive performance (secondary outcome) were assessed at baseline and 6 months later. Brain ketone metabolism increased by 230% for subjects on the kMCT (P < .001) whereas brain glucose uptake remained unchanged. Measures of episodic memory, language, executive function, and processing speed improved on the kMCT versus baseline. Increased brain ketone uptake was positively related to several cognitive measures. Seventy-five percent of participants completed the intervention. A dose of 30 g/day of kMCT taken for 6 months bypasses a significant part of the brain glucose deficit and improves several cognitive outcomes in MCI.

Identifiants

pubmed: 31027873
pii: S1552-5260(19)30011-1
doi: 10.1016/j.jalz.2018.12.017
pii:
doi:

Substances chimiques

Ketones 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-634

Informations de copyright

Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Auteurs

Mélanie Fortier (M)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada. Electronic address: melanie.fortier2@usherbrooke.ca.

Christian-Alexandre Castellano (CA)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada.

Etienne Croteau (E)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Department of Pharmacology and Physiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Francis Langlois (F)

CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada.

Christian Bocti (C)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Valérie St-Pierre (V)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada.

Camille Vandenberghe (C)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada.

Michaël Bernier (M)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Department of Pharmacology and Physiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Maggie Roy (M)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Department of Pharmacology and Physiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Computer Science, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Maxime Descoteaux (M)

Department of Computer Science, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Kevin Whittingstall (K)

Department of Radiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada; CR-CHUS, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada.

Martin Lepage (M)

CR-CHUS, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Nuclear Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada; Department of Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.

Éric E Turcotte (ÉE)

CR-CHUS, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Nuclear Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada; Department of Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.

Tamas Fulop (T)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Stephen C Cunnane (SC)

Research Center on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada; Department of Pharmacology and Physiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH